Alkermes (NASDAQ:ALKS) EVP Sells $267,480.00 in Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $29.72, for a total value of $267,480.00. Following the transaction, the executive vice president owned 89,389 shares in the company, valued at approximately $2,656,641.08. The trade was a 9.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Alkermes Trading Up 0.3%

Shares of NASDAQ:ALKS traded up $0.08 during trading on Wednesday, reaching $29.28. 1,753,117 shares of the company traded hands, compared to its average volume of 1,842,072. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32. The firm has a market capitalization of $4.88 billion, a price-to-earnings ratio of 20.48, a P/E/G ratio of 7.28 and a beta of 0.53. The business’s fifty day moving average is $31.60 and its 200-day moving average is $30.24.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The firm had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The company’s quarterly revenue was down 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, sell-side analysts predict that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alkermes

A number of institutional investors have recently added to or reduced their stakes in the company. Assetmark Inc. lifted its position in Alkermes by 933.8% during the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 747 shares during the period. Cullen Frost Bankers Inc. purchased a new position in Alkermes during the 4th quarter valued at about $28,000. Johnson Financial Group Inc. bought a new stake in Alkermes during the third quarter worth about $31,000. UMB Bank n.a. grew its holdings in Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after purchasing an additional 446 shares during the period. Finally, Hantz Financial Services Inc. increased its stake in shares of Alkermes by 395.6% during the third quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after purchasing an additional 989 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ALKS shares. HC Wainwright reiterated a “neutral” rating and issued a $43.00 price objective on shares of Alkermes in a report on Thursday, February 26th. Royal Bank Of Canada dropped their price target on Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Zacks Research cut shares of Alkermes from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Wall Street Zen downgraded shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Wells Fargo & Company raised their target price on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.